Defective Cytostatic Activity of Pulmonary Alveolar Macrophages in Primary Lung Cancer: Discussion (2)

Defective Cytostatic Activity of Pulmonary Alveolar Macrophages in Primary Lung Cancer: Discussion (2)We have shown that there is a defect of PAM activation for tumor cell cytostasis in patients with lung cancer and that this defect does not appear to be related to smoking, since when cytostatic activity was compared between current smokers, ex-smokers, and nonsmokers within each group, no significant differences were found. buy prednisone

It was possible in our study to overcome the macrophage cytostatic abnormality by stimulating macrophages with large doses of recombinant 7-interferon, a known macrophage-activating agent. The dose of 7-interferon (1,250 units/ml) was chosen, as we have found this previously to induce maximal PAM stimulation for cytostasis. Significant increases in cytostatic activity were also achievable with a dose of 7-interferon of 125 units/ml (data not shown), a dose which is more easily comparable with the sorts of doses given therapeutically by the parenteral route in human cancer therapy. In vivo doses vary, but regimens may include doses of up to 2 X 107units/m2 daily. Higher doses of 7-interferon might be tolerated if given via an alternative route, such as by intranasal or intratracheal instillation or by packaging in liposomes, as has been used for the administration of other macrophage-activating agents in rodents. At present, these approaches have not been explored in man.

This entry was posted in Pulmonary Function and tagged , , , , , , .